|Bid||179.67 x 1400|
|Ask||180.34 x 1000|
|Day's range||176.73 - 184.37|
|52-week range||119.95 - 192.00|
|Beta (5Y monthly)||1.06|
|PE ratio (TTM)||17.97|
|Earnings date||31 Jan 2022 - 04 Feb 2022|
|Forward dividend & yield||0.28 (0.16%)|
|Ex-dividend date||20 Jan 2022|
|1y target est||188.82|
PerkinElmer (PKI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
WALTHAM, Mass., November 29, 2021--PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the performance of its SARS-CoV-2 RT-PCR assays are not impacted by the emergence of Omicron (B.1.1.529), a variant of concern that was recently identified by the World Health Organization (WHO).
PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.